- Home
- BSII vs CHRS Comparison
BSII vs CHRS Comparison
Compare BSII & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSII
- CHRS
- Stock Information
- Founded
- BSII 2024
- CHRS 2010
- Country
- BSII Hong Kong
- CHRS United States
- Employees
- BSII N/A
- CHRS 235
- Industry
- BSII
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BSII
- CHRS Health Care
- Exchange
- BSII Nasdaq
- CHRS Nasdaq
- Market Cap
- BSII 189.9M
- CHRS 134.4M
- IPO Year
- BSII 2024
- CHRS 2014
- Fundamental
- Price
- BSII $10.01
- CHRS $1.16
- Analyst Decision
- BSII
- CHRS Strong Buy
- Analyst Count
- BSII 0
- CHRS 4
- Target Price
- BSII N/A
- CHRS $5.38
- AVG Volume (30 Days)
- BSII 4.2K
- CHRS 2.4M
- Earning Date
- BSII 01-01-0001
- CHRS 03-12-2025
- Dividend Yield
- BSII N/A
- CHRS N/A
- EPS Growth
- BSII N/A
- CHRS N/A
- EPS
- BSII N/A
- CHRS N/A
- Revenue
- BSII N/A
- CHRS $304,340,000.00
- Revenue This Year
- BSII N/A
- CHRS $2.47
- Revenue Next Year
- BSII N/A
- CHRS N/A
- P/E Ratio
- BSII N/A
- CHRS N/A
- Revenue Growth
- BSII N/A
- CHRS 44.19
- 52 Week Low
- BSII $9.86
- CHRS $0.66
- 52 Week High
- BSII $10.30
- CHRS $2.87
- Technical
- Relative Strength Index (RSI)
- BSII N/A
- CHRS 38.01
- Support Level
- BSII N/A
- CHRS $1.03
- Resistance Level
- BSII N/A
- CHRS $1.39
- Average True Range (ATR)
- BSII 0.00
- CHRS 0.14
- MACD
- BSII 0.00
- CHRS -0.03
- Stochastic Oscillator
- BSII 0.00
- CHRS 14.04
About BSII Black Spade Acquisition II Co Class A Ordinary Share
Black Spade Acquisition II Co is a blank check company.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.